Cargando…

Targeting STAT3 in Cancer with Nucleotide Therapeutics

Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3 has commonly been considered an “undruggable” target for therapy; thus, much research has focused on ta...

Descripción completa

Detalles Bibliográficos
Autores principales: K. Lau, Yue-Ting, Ramaiyer, Malini, E. Johnson, Daniel, R. Grandis, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896109/
https://www.ncbi.nlm.nih.gov/pubmed/31671769
http://dx.doi.org/10.3390/cancers11111681
_version_ 1783476708332011520
author K. Lau, Yue-Ting
Ramaiyer, Malini
E. Johnson, Daniel
R. Grandis, Jennifer
author_facet K. Lau, Yue-Ting
Ramaiyer, Malini
E. Johnson, Daniel
R. Grandis, Jennifer
author_sort K. Lau, Yue-Ting
collection PubMed
description Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3 has commonly been considered an “undruggable” target for therapy; thus, much research has focused on targeting upstream pathways to reduce the expression or phosphorylation/activation of STAT3 in tumor cells. Recently, however, novel approaches have been developed to directly inhibit STAT3 in human cancers, in the hope of reducing the survival and proliferation of tumor cells. Several of these agents are nucleic acid-based, including the antisense molecule AZD9150, CpG-coupled STAT3 siRNA, G-quartet oligodeoxynucleotides (GQ-ODNs), and STAT3 decoys. While the AZD9150 and CpG-STAT3 siRNA interfere with STAT3 expression, STAT3 decoys and GQ-ODNs target constitutively activated STAT3 and modulate its ability to bind to target genes. Both STAT3 decoy and AZD9150 have advanced to clinical testing in humans. Here we will review the current understanding of the structures, mechanisms, and potential clinical utilities of the nucleic acid-based STAT3 inhibitors.
format Online
Article
Text
id pubmed-6896109
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68961092019-12-23 Targeting STAT3 in Cancer with Nucleotide Therapeutics K. Lau, Yue-Ting Ramaiyer, Malini E. Johnson, Daniel R. Grandis, Jennifer Cancers (Basel) Review Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3 has commonly been considered an “undruggable” target for therapy; thus, much research has focused on targeting upstream pathways to reduce the expression or phosphorylation/activation of STAT3 in tumor cells. Recently, however, novel approaches have been developed to directly inhibit STAT3 in human cancers, in the hope of reducing the survival and proliferation of tumor cells. Several of these agents are nucleic acid-based, including the antisense molecule AZD9150, CpG-coupled STAT3 siRNA, G-quartet oligodeoxynucleotides (GQ-ODNs), and STAT3 decoys. While the AZD9150 and CpG-STAT3 siRNA interfere with STAT3 expression, STAT3 decoys and GQ-ODNs target constitutively activated STAT3 and modulate its ability to bind to target genes. Both STAT3 decoy and AZD9150 have advanced to clinical testing in humans. Here we will review the current understanding of the structures, mechanisms, and potential clinical utilities of the nucleic acid-based STAT3 inhibitors. MDPI 2019-10-29 /pmc/articles/PMC6896109/ /pubmed/31671769 http://dx.doi.org/10.3390/cancers11111681 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
K. Lau, Yue-Ting
Ramaiyer, Malini
E. Johnson, Daniel
R. Grandis, Jennifer
Targeting STAT3 in Cancer with Nucleotide Therapeutics
title Targeting STAT3 in Cancer with Nucleotide Therapeutics
title_full Targeting STAT3 in Cancer with Nucleotide Therapeutics
title_fullStr Targeting STAT3 in Cancer with Nucleotide Therapeutics
title_full_unstemmed Targeting STAT3 in Cancer with Nucleotide Therapeutics
title_short Targeting STAT3 in Cancer with Nucleotide Therapeutics
title_sort targeting stat3 in cancer with nucleotide therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896109/
https://www.ncbi.nlm.nih.gov/pubmed/31671769
http://dx.doi.org/10.3390/cancers11111681
work_keys_str_mv AT klauyueting targetingstat3incancerwithnucleotidetherapeutics
AT ramaiyermalini targetingstat3incancerwithnucleotidetherapeutics
AT ejohnsondaniel targetingstat3incancerwithnucleotidetherapeutics
AT rgrandisjennifer targetingstat3incancerwithnucleotidetherapeutics